Kailera Therapeutics shows a highly favorable modeled asymmetry with 68.5% upside versus 15% downside and notable insider buying of $8 million, but the quality composite sits below the engine's floor, its single reported earnings quarter missed sharply, and the speculative classification for a binary biotech outcome caps position sizing despite the passed momentum and asymmetry gates.
Thesis pillars
- Quality Below Floor→Stable
- Favorable Modeled Asymmetry→Stable
- Notable Insider Buying→Stable
- +2 more pillars — see the Why tab for full reasoning
Kailera Therapeutics, Inc. (KLRA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $12.83: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides,... Read more
Sell if holding. Engine safety override at $12.83: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 36d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-23Recent Developments — Kailera Therapeutics, Inc.
Latest news
- NEWS Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’ — benzinga Sep 11, 2026 positive
- NEWS Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate — benzinga Aug 12, 2026 negative
- NEWS Why Is Kailera Therapeutics Stock Falling Tuesday? — benzinga Jul 7, 2026 negative
- NEWS Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Rec — benzinga Jul 7, 2026 positive
Generated 2026-09-23T16:32:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.83: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.93. Score 4.7/10, moderate confidence.
Take-profit target: $18.40 (+43.4% upside). Prior stop was $11.93. Stop-loss: $11.93.
DATA_ISSUE: analyst_target_implausible (raw $42.40 vs price $12.83 — ratio 3.3×). Rejected, falling back to technical TP.; Quality below floor (2.5 < 4.0).
Kailera Therapeutics, Inc. trades at a P/E of N/A (forward -3.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
12 analysts cover KLRA with a consensus score of 4.3/5. Average price target: $42.
What does Kailera Therapeutics, Inc. do?Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and...
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.